Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 mRNA vaccination elicits broad and potent Fc effector functions to VOCs in vulnerable populations

Andrew P. Hederman, Harini Natarajan, Joshua A. Wiener, Peter F. Wright, Evan M. Bloch, Aaron A.R. Tobian, Andrew D. Redd, Joel N. Blankson, Amihai Rottenstreich, Gila Zarbiv, Dana Wolf, Tessa Goetghebuer, Arnaud Marchant, View ORCID ProfileMargaret E. Ackerman
doi: https://doi.org/10.1101/2022.09.15.22280000
Andrew P. Hederman
1Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harini Natarajan
2Department of Immunology and Microbiology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua A. Wiener
1Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter F. Wright
3Department of Pediatrics, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evan M. Bloch
4Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aaron A.R. Tobian
4Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew D. Redd
5Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA
6Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel N. Blankson
5Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amihai Rottenstreich
7Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gila Zarbiv
8Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dana Wolf
8Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tessa Goetghebuer
9Institute for Medical Immunology, Université libre de Bruxelles, Charleroi, Belgium
10Pediatric Department, CHU St Pierre, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arnaud Marchant
9Institute for Medical Immunology, Université libre de Bruxelles, Charleroi, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret E. Ackerman
1Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
2Department of Immunology and Microbiology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Margaret E. Ackerman
  • For correspondence: margaret.e.ackerman@dartmouth.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

SARS-CoV-2 variants have continuously emerged even as highly effective vaccines have been widely deployed. Reduced neutralization observed against variants of concern (VOC) raises the question as to whether other antiviral antibody activities are similarly compromised, or if they might compensate for lost neutralization activity. In this study, the breadth and potency of antibody recognition and effector function was surveyed in both healthy individuals as well as immunologically vulnerable subjects following either natural infection or receipt of an mRNA vaccine. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observed similar binding and functional breadth for healthy and immunologically vulnerable populations. In contrast, considerably greater functional antibody breadth and potency across VOC was associated with vaccination than prior infection. However, greater antibody functional activity targeting the endemic coronavirus OC43 was noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains that was associated with exposure history. Probing the full-length spike and receptor binding domain (RBD) revealed that antibody-mediated Fc effector functions were better maintained against full-length spike as compared to RBD. This analysis of antibody functions in healthy and vulnerable populations across a panel of SARS-CoV-2 VOC and extending through endemic alphacoronavirus strains suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as the pandemic progresses and novel variants continue to evolve.

One Sentence Summary As compared to natural infection with SARS-CoV-2, vaccination drives superior functional antibody breadth raising hopes for candidate universal CoV vaccines.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, as well as extramural support from the National Institute of Allergy and Infectious Diseases (R01AI120938, R01AI120938S1 and R01AI128779 to A.A.R.T), National Heart Lung and Blood Institute (K23HL151826 to E.M.B), National Cancer Institute (2 P30 CA 023108-41 to M.E.A.), National Institute of General Medical Sciences (P20-GM113132 BioMT Molecular Tools Core to M.E.A.). A.M. is Research Director at the F.R.S., FNRS, Belgium.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Subjects provided informed written consent and studies were reviewed and approved by IRBs at individual collection sites and Dartmouth.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted September 18, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 mRNA vaccination elicits broad and potent Fc effector functions to VOCs in vulnerable populations
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 mRNA vaccination elicits broad and potent Fc effector functions to VOCs in vulnerable populations
Andrew P. Hederman, Harini Natarajan, Joshua A. Wiener, Peter F. Wright, Evan M. Bloch, Aaron A.R. Tobian, Andrew D. Redd, Joel N. Blankson, Amihai Rottenstreich, Gila Zarbiv, Dana Wolf, Tessa Goetghebuer, Arnaud Marchant, Margaret E. Ackerman
medRxiv 2022.09.15.22280000; doi: https://doi.org/10.1101/2022.09.15.22280000
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 mRNA vaccination elicits broad and potent Fc effector functions to VOCs in vulnerable populations
Andrew P. Hederman, Harini Natarajan, Joshua A. Wiener, Peter F. Wright, Evan M. Bloch, Aaron A.R. Tobian, Andrew D. Redd, Joel N. Blankson, Amihai Rottenstreich, Gila Zarbiv, Dana Wolf, Tessa Goetghebuer, Arnaud Marchant, Margaret E. Ackerman
medRxiv 2022.09.15.22280000; doi: https://doi.org/10.1101/2022.09.15.22280000

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1096)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9772)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2312)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1561)
  • Health Policy (736)
  • Health Systems and Quality Improvement (603)
  • Hematology (238)
  • HIV/AIDS (504)
  • Infectious Diseases (except HIV/AIDS) (11649)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (238)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2144)
  • Nursing (134)
  • Nutrition (337)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1179)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2182)
  • Public and Global Health (4661)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)